Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide effect on intramyocardial triglyceride content in obese patients with type 2 diabetes
2010-022792-57Phase 3Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Change in intramyocardial triglyceride content after 26 weeks. Started Sep 2010; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2010-022792-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022792-57.